On September 28, Moderna, Inc. declined 4.77% in regular trading, trading at approximately $193.33 per share, with turnover of $3.82 billion. The pullback comes after the stock surged roughly 29% over the prior week and over 38% through September, driven by its personalized mRNA cancer vaccine pipeline.

The recent rally was catalyzed by Moderna's announcement that three research abstracts for its individualized cancer vaccine intismeran autogene were accepted at the European Society for Medical Oncology annual meeting, with the pivotal Phase 3 INTerpath-001 melanoma data set to be presented on October 24. The stock had briefly breached the $200 level, hitting a 52-week high of $202.67. However, the current price sits significantly above the analyst consensus target of approximately $112.72, with even the most bullish Wall Street target at $180. Options markets had shown heavy bullish positioning in recent sessions, including a $9.18 million deep in-the-money call purchase and a $3.38 million bull call spread, suggesting elevated speculative activity ahead of the ESMO catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)